[ad_1]
On December 11, the pharmaceutical company AstraZeneca began clinical trials of the combined use of its AZD1222 COVID-19 vaccine along with the Russian drug Sputnik V.
This was reported by the press service of the company. The research will involve volunteers over the age of 18.
AstraZeneca clarified that both vaccines are based on the same principle using adenovirus.
The report noted that studying various options for the use of COVID-19 drugs will develop a variety of approaches to prevent coronavirus infection.
Additionally, the combined efforts of UK and Russian pharmacists may lead to an increase in the body’s immune response to the effects of the virus.
In addition, the combination of vaccines will make the drugs more accessible to people.
European Medical Agency (EMA) press service representative Violetta Pashova told Interfax-Ukraine that applications for admission to the market of vaccines against COVID-19 coronavirus from two pharmaceutical companies, Pfizer / BioNTech and Moderna, are already being considered. Biotech Spain.
The agency has also begun preliminary screening of Janssen-Cilag International NV and AstraZeneca.
As reported by OBOZREVATEL, the British-Swedish company AstraZeneca’s vaccine, developed jointly with the University of Oxford, had average efficacy in 70% of cases.
